Capricor/$CAPR
1D1W1MYTD1Y5YMAX
Capital at risk
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Ticker
- $CAPR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 231
- Headquarters
- San Diego, United States
- Website
- www.capricor.com
Capricor Metrics
BasicAdvanced
$486M
-
-$2.47
0.53
-
Price and volume
Market cap
$486M
Beta
0.53
52-week high
$40.37
52-week low
$2.96
Average daily volume
8.2M
Financial strength
Current ratio
7.346
Quick ratio
7.219
Long term debt to equity
0.364
Total debt to equity
0.053
Interest coverage (TTM)
-44.38%
Profitability
EBITDA (TTM)
-133.093
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-33.63%
Return on equity (TTM)
-73.70%
Valuation
Price to book
1.73
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
-3.381
Free cash flow yield (TTM)
-29.58%
Free cash flow per share (TTM)
-2.473
Growth
Earnings per share change (TTM)
48.91%
3-year earnings per share growth (CAGR)
28.33%
10-year earnings per share growth (CAGR)
-12.22%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Analyst projections of the future price of Capricor stock.
Bulls say / Bears say
HOPE-3 met its primary endpoint, with deramiocel slowing upper-limb decline by 54% versus placebo at 12 months (p=0.03). The results were published in The Lancet after independent peer review, giving the lead programme stronger external validation. (Capricor Therapeutics)
The FDA accepted Capricor’s major BLA amendment and moved the action date to 22 November 2026. The narrower proposed indication focuses on upper-limb function, where HOPE-3 produced its clearest result, while the FDA reviews 24-month follow-up and additional analyses. (Capricor Therapeutics, BioSpace)
Longer-term data could strengthen the case if they confirm durable benefit and tolerability. Capricor has reported five-year HOPE-2 open-label data and is due to present 24-month HOPE-3 results, with 82 of the original 106 patients reaching that time point. (Capricor Therapeutics, Capricor Therapeutics)
The FDA advisory committee voted 9–3 that the available evidence did not support deramiocel’s effectiveness for DMD cardiomyopathy. Although the vote was non-binding and did not cover the proposed upper-limb indication, it is a significant setback for the original regulatory case. (Capricor Therapeutics)
The trial data face regulatory scrutiny over the statistical analysis. Capricor disclosed that the all-patient LVEF result changed from p=0.04 in topline reporting to p=0.09 under the pre-specified model, and that an FDA inspection produced one Form 483 observation. (Capricor Therapeutics)
Capricor remains loss-making and has no approved product revenue to fund operations. Its latest outlook says existing resources cover at least the next twelve months under the current plan, so a regulatory delay or rejection could increase financing needs and dilution risk. (Capricor Therapeutics, Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Capricor News
AllArticlesVideos
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Business Wire7 hours ago
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action
Newsfile Corp20 hours ago
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
Newsfile Corp1 day ago
Funds containing Capricor
AllEURGBPUSD
Fund name | Fund size | $CAPR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.